Abstract:ETHNOPHARMACOLOGICAL RELEVANCE:Polysaccharides and small molecules commonly co-exist in decoctions of traditional Chinese medicines (TCMs). Our previous study outlined that ginseng polysaccharides (GP) could interact with co-existing ginsenosides to produce synergistic effect in an over-fatigue and acute cold stress model via gut microbiota involved mechanisms.AIM OF THE STUDY:This study aimed to verify the interactions by examining the impact of GP on oral pharmacokinetics of ginsenoside Rb1 (Rb1), the dominant protopanoxadiol (PPD)-type ginsenoside in Ginseng, on a dextran sulphate sodium (DSS) induced experimental colitis model which was characterized by gut dysbiosis, and to delineate the underlying mechanisms in vitro.MATERIALS AND METHODS:Rats received drinking water (normal group), 5% DSS (UC group), or 5% DSS plus daily oral administration of GP (GP group) for 7 days and fecal samples were collected on day -3, 0 and 6. On day 7 all animals received an oral dosage of Rb1 and blood samples were withdrawn for pharmacokinetic study. The in vitro metabolism study of Rb1 in gut microbiota from normal and UC rats and the transport study of Rb1 across Caco-2 cell monolayer were carried out in presence/absence of GP. Rb1 and its bacterial metabolites ginsenoside Rd (Rd), ginsenoside F2 (F2), Compound K (CK) and PPD were determined using LC-MS/MS. Total and target bacteria in fecal samples were determined by using 16S rRNA-based RT-PCR. β-Glucosidase activity was determined by measuring 4-nitrophenol formed from 4-nitrophenyl-β-D-glucopyranoside hydrolysis.RESULTS:DSS induction did not alter AUC0-t and Cmax of Rb1, which, however, were doubled together with elevated AUC0-t of the metabolites, in particular Rd and CK, in GP group. GP influenced the microbial composition and showed a prebiotic-like effect. Accordingly, GP treatment could partially restore the β-glucosidase activity which was reduced by DSS induction. The presence of GP resulted in quicker microbial metabolism of Rb1 and higher Rd formation in first 8 h of incubation, while the impact on F2 and CK formation/conversion became obvious after 8 h. More interestingly, GP slightly stimulated Caco-2 cell growth and facilitated Rb1 transport across the Caco-2 monolayer in both directions, increasing the Papp of Rb1 from 10-7 cm/s to 10-6 cm/s.CONCLUSIONS:GP alleviated DSS-induced colitis-like symptoms and enhanced the systemic exposure of Rb1 through enhancing microbial deglycosylation and intestinal epithelial absorption of Rb1. These findings further demonstrated the important role of gut microbiota in the multifaceted action of polysaccharides in the holistic actions of traditional decoction of TCMs.

Ginsenoside Compound K Promotes Intestinal Peristalsis and the Pharmacokinetic of Metabolite 20(S)-Protopanaxadiol in Relation to Diarrhea

The edible <i>Lactobacillus paracasei</i> X11 with Konjac glucomannan promotes intestinal motility in zebrafish

In vivo pharmacokinetics of ginsenoside compound K mediated by gut microbiota

Ginsenoside CK Alleviates DSS-Induced IBD in Mice by Regulating Tryptophan Metabolism and Activating Aryl Hydrocarbon Receptor via Gut Microbiota Modulation

Ginseng Polysaccharides Enhanced Ginsenoside Rb1 and Microbial Metabolites Exposure Through Enhancing Intestinal Absorption and Affecting Gut Microbial Metabolism.

Qualitatively and quantitatively investigating the metabolism of 20(S)-protopanaxadiol-type ginsenosides by gut microbiota of different species

Food and Sex-Related Impacts on the Pharmacokinetics of a Single-Dose of Ginsenoside Compound K in Healthy Subjects.

Microbiota, Co-Metabolites, and Network Pharmacology Reveal the Alteration of the Ginsenoside Fraction on Inflammatory Bowel Disease.

Pharmacokinetic Characterization of Ginsenoside Rd, an Ulcerative Colitis Targeted-Therapy Candidate, in Gastrointestinal Tract in Vivo by Hplc

A narrative review of the pharmacology of ginsenoside compound K

Progress in Pharmacological Actions of Ginsenoside Compound K,an Active Metabolite of Protopanaxadiol Type Saponins

Single- and Multiple-Dose Trials to Determine the Pharmacokinetics, Safety, Tolerability, and Sex Effect of Oral Ginsenoside Compound K in Healthy Chinese Volunteers.

A review of biotransformation and pharmacology of ginsenoside compound K.

Ginseng Polysaccharides and its Effective Subfraction Protects Against Dextran Sodium Sulfate-Induced Colitis via Regulating NF-κB Signaling Pathway, Recovering Intestinal Barrier and Adjusting Gut Microbiota

Different absorption and metabolism of ginsenosides after the administration of total ginsenosides and decoction of<i>Panax ginseng</i>

20(S)- Protopanaxadiol Saponins Isolated from Panax Notoginseng Target the Binding of HMGB1 to TLR4 Against Inflammation in Experimental Ulcerative Colitis

Insights into gastrointestinal microbiota-generated ginsenoside metabolites and their bioactivities

Identification and Quantitative Investigation of the Effects of Intestinal Microflora on the Metabolism and Pharmacokinetics of Notoginsenoside Fc Assayed by Liquid Chromatography with Electrospray Ionization Tandem Mass Spectrometry

Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice

Ginsenoside Metabolite Compound K Promotes Recovery Of Dextran Sulfate Sodium- Induced Colitis And Inhibits Inflammatory Responses By Suppressing Nf-Kappa B Activation

Pharmacological effects of biologically synthesized ginsenoside CK-rich preparation (AceCK40) on the colitis symptoms in DSS-induced Caco-2 cells and C57BL mice